MagVenture announces FDA clearance of Pain Therapy in the US: A non-invasive approach to CHRONIC PAIN relief

December 05, 2023 12:00 AM AEDT | By EIN Presswire

Google News:

MagVenture announces FDA clearance of Pain Therapy in the US: A non-invasive approach to CHRONIC PAIN relief — Image source: EIN Presswire

Recent News

Brambles (ASX:BXB) Climbs in 2025: A Strategic Look at This ASX300 Log...

Insights into (ASX:WTC) and (ASX:PLS) Amid Market Shifts

Can Westpac (ASX:WBC) Outperform the ASX300 in 2025?

Oil Volatility Shakes Market But ASX300 Investors Stay Focused

ALPHARETTA, GA, UNITED STATES, December 4, 2023 /EINPresswire.com/ -- MagVenture, a renowned global manufacturer of Magnetic Stimulation devices, celebrates a new milestone with the launch of MagVenture Pain Therapy—an FDA-cleared solution for chronic pain relief. With over 30 years of experience, MagVenture has been at the forefront of using magnetic stimulation to enhance the lives of patients suffering from depression and other psychiatric disorders. Now, with the introduction of MagVenture Pain Therapy, the company is extending its expertise to bring those solutions to chronic pain.

“Today, we take all our experience and commitment to patient care to new heights. We're excited about the possibilities of expanding our technology to reach individuals who are living with chronic pain, offering them our perspective on pain management", says Kerry Rome, Senior Vice President of Sales at MagVenture Inc. He expressed the company's pride in having helped countless patients with depression using their TMS technology over the years.

MagVenture Pain Therapy employs powerful focused magnetic pulses directed near the injured nerve, providing a non-invasive, painless approach to stimulate peripheral nerves for clinically proven pain relief. Unlike traditional treatments for chronic nerve pain, MagVenture Pain Therapy offers a unique neuromodulation technique.

What sets MagVenture Pain Therapy apart is its versatility and ease of use. Patients can experience relief with sessions lasting just 13 minutes, spread over a two-month period. This non-pharmacologic treatment is a significant advancement for those seeking a safe, efficient alternative to surgery or medication for chronic pain relief.

For more information about MagVenture Pain Therapy and its potential applications, please visit www.magventurepaintherapy.com.

MagVenture Pain TherapyTM FDA Indications for Use: To stimulate peripheral nerves for relief of chronic intractable, post-traumatic and post-surgical pain for patients 18 years or older

About MagVenture
MagVenture is a market-leading manufacturer of non-invasive Transcranial Magnetic Stimulation (TMS) systems worldwide. Privately owned with headquarters in Denmark, MagVenture has been pioneering leading-edge TMS solutions for more than 30 years. MagVenture’s TMS systems are used for both research and treatment in the fields of psychiatry, neurophysiology, neurology, cognitive neuroscience, and rehabilitation.

For more information, please contact:
Kerry Rome, Senior Vice President, MagVenture Inc. (USA) | +1 888 624 7764 | [email protected]

For media inquiries, please contact:
Esben Rosenberg, Global Marketing Manager, MagVenture A/S (DK) | +45 51465592 | [email protected]

Kerry Rome
MagVenture, Inc.
+1 888-624-7764
[email protected]

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.